The role of co-inhibitory signals driven by CTLA-4 in immune system;Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire

Medecine/Sciences

Volumn 27, Issue 10, 2011, Pages 842-849

  Olive, Daniel ^a,b,c,d   Thi, Suong Ie ^a,b,c,d   Xerri, Luc ^a   Hirsch, Ivan ^a   Nunès, Jacques A ^a  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d IBiSA cancer immunomonitoring platform   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROTEIN KINASE; T LYMPHOCYTE RECEPTOR;

ANIMAL; ANTIGEN PRESENTING CELL; BIOLOGICAL MODEL; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC; NEOPLASMS, EXPERIMENTAL; PERIPHERAL TOLERANCE; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 80455176697     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20112710012     Document Type: Review

References (37)

1. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992 ; 71: 1065-8. (Pubitemid 23016541)
2. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Anna Rev Immunol 1993; 11:191-212. (Pubitemid 23115006)
3. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sa USA 1989; 86 :1333-7. (Pubitemid 19061540)
4. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173:721-30.
5. Cerdan C, Martin y, Courcoul M, et af. CD28 costimulation up-regulates long-term IL-2R beta expression in human T cells through combined transcriptional and post-transcriptional regulation. J Immunol 1995; 154:1007-13.
6. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995 ; 3: 87-98.
7. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur Immunol 1997 ; 27 : 239-47. (Pubitemid 27046084)
8. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by theTcell accessory molecule CD28. Science 1991; 251: 313-6. (Pubitemid 21916882)
9. Granelli-Piperno A, Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol 1991; 147 : 2734-9.
10. Pages F, Ragueneau M, Rottapel R, et af. Binding of phosphatidylinositol- 3-OH kinase to CD28 is required forT-cell signalling. Nature 1994; 369: 327-9. (Pubitemid 24159544)
11. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26.
12. Sanchez-Lockhart M, Marin E, Graf B, et al. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J Immunol 2004; 173:7120-4. (Pubitemid 39628145)
13. Miller J, Baker C, Cook K, et af. Two pathways of costimulation through CD28. Immunol Res 2009; 13 fevrier (online).
14. Huang J, Lo PF, Zal T, et al. CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse. Proc Natl Acad Sci USA 2002 ; 99 : 9369-73. (Pubitemid 34764620)
15. Saito T, yokosuka T, Hashimoto-Tone A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett 2010 ; 584 :4865-71.
16. Linsley PS, Golstein P. Lymphocyte activation: T-cell regulation by CTLA-4. Curt Biol 1996; 6 : 398-400. (Pubitemid 126656286)
17. Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994; 180:2049-58. (Pubitemid 24351586)
18. Truneh A, Reddy M, Ryan P, et al. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol Immunol 1996; 33:321-34.
19. Van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.; Exp Med 1997; 185 : 393-403. (Pubitemid 27078358)
20. Laurent S, Carrega P, Savenno D, et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010; 7 1 : 934-41.
21. Tivol EA, Borriello F, Schweitzer AN, et af. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
22. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8.
23. Walunas TL, Lenschow DJ, Bakker Cy, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13.
24. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8. T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA 2010; 108: 266-71.
25. Jain N, Nguyen H, Chambers C, KangJ. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 2010 ; 107:1524-8.
26. Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010; 11:129-35.
27. Dustin ML. Insights into function of the immunological synapse from studies with supported planar bilayers. Curr Top Microbiol Immunol 2010 ; 340 : 1-24.
28. yokosuka T, Kobayashi W, Sakata-Sogawa K, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclysters and protein kinase C theta translocation. Immunity 2008 ; 29: 589-601.
29. yokosuka T, Kobayashi W, Takamatsu M, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 2010; 33 : 326-39.
30. Curran MA, Montalvo W, yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-80.
31. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA- 4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.,/ fxp Med 1999; 190 : 355-66. (Pubitemid 29374833)
32. Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009 ; 229 : 5-11.
33. Olive D. Corecépteurs lymphocytaires. Med Sci (Paris) 2006; 22 :1069-74.
34. Watanabe N, Gavneli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4 : 670-9. (Pubitemid 36874444)
35. Serriari NE, Gondois-Rey F, Guillaume Y, et al. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.; Immunol 2010; 185 : 3140-8.
36. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12:864-72. (Pubitemid 47328229)
37. Robert C, Matteus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011;27:850-8.